August 21, 2017August 21, 2017

Prometic, SRAM to Jointly Advance 3 Fibrosis, Scleroderma Therapies for Booming Chinese Market

Canada’s Prometic Life Sciences and Shenzhen Royal Asset Management (SRAM) will jointly manufacture, develop and commercialize three fibrosis and scleroderma therapies in China, the two companies announced. namely the drugs PBI-4050, PBI-4547 and PBI-4425. A new subsidiary, ... Read more

June 14, 2016June 14, 2016

Boehringer Ingelheim, Harvard Scientists Partner to Develop Novel Treatments for IPF, Other Fibrotic Diseases

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim and Harvard Stem Cell Institute’s (HSCI) Harvard Fibrosis Network recently announced a new research partnership to find novel treatments for fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), chronic kidney ... Read more